A few days ago, the eighth CR Healthcare Talk special report of Huaxing Capital invited Dr. Yang Xuanming, an expert in tumor immune cell therapy and the current chief scientist of Longyao Bio, to share with you the march to cell therapy 2.0: universal CAR-T and solid tumor therapy. After successfully leading Yescarta to be approved for listing, the former core executives of Kite Pharma jointly founded the cutting-edge company Allogene, which once again detonated the immune cell therapy market with the general CAR-T technology. Evaluation of gene editing technology to realize allogeneic UCAR-T therapy, peaking the current situation of complex and high cost of traditional CAR-T preparation, which is expected to bring good news to more cancer patients, and won the Nasdaq Biotechnology in less than a year after its establishment The market value of listed companies is crowned.
At the same time, solid tumor immune cell therapy has become a market where many companies are competing for the foreshore. Adaptimmune's TCR-T therapy has successively entered the clinical trial stage, NantKwest's NK cell therapy, MDAnderson Cancer Center's CAR-NK therapy, etc. are also in full swing, pointing to the development of solid tumors.
What kind of China story will the rising general CAR-T and solid tumor therapy have?
Dr. Yang Xuanming reported the research breakthroughs and industrial transformation achievements of Shanghai Longyao Biotechnology Co., Ltd. in general CAR-T and solid tumor therapy to more than 100 participants from the investment and technology circles. The participants were very excited!
Professor Yang Xuanming focused on the characteristics of Shanghai Longyao Bio-Universal CAR-T: First, master the core patented technology, the patented technology eliminates the side effects of CVHD, and realizes a highly versatile T cell platform; Second, the product is safe and controllable, and the switching system ensures UCAR -T is safe, reliable and more economical; third, it has significant differentiated competitive advantages, compared with top international UCAR-T companies; fourth, excellent clinical effects, preclinical animal experiments and exploratory clinical research It has shown excellent efficacy in CAR-T, and is familiar with autologous CAR-T.
Professor Yang Xuanming also introduced Shanghai Longyao Bio's solutions for solid tumor treatment: Shanghai Longyao Bio has built a comprehensive system of tumor immune cell therapy based on clinical needs. The 12 product pipelines it has developed focus on immune corresponding cells and assist in Immunoregulatory cells and immune activation cells, combined cell therapy solutions have comprehensively improved the comprehensive capabilities of providing immune cells, including: tumor infiltration ability, expansion ability, anti-exhaustion ability, tumor microenvironment inhibition resistance, killing ability, avoidance Systemic side effects caused by secretion and avoid potential tumorigenic risks.
At present, Shanghai Longyao Bio's general-purpose CAR-T and new CAR-T products have entered the clinical research stage. After careful evaluation, such as preliminary communication, inspection, program review, and on-site inspection, all of them were approved by the expert committee and the ethics committee.
Longyao Biology and Nanjing Medical University signed a strategic cooperation
Longyao Biology and Nanjing Medical University signed a strategic cooperation
Professor Yao Yi, a former US FDA official, has been appointed as the co-chairman and chief medical officer of Shanghai Longyao Biology. Professor Yao Yi has 18 years of FDA new drug clinical review work experience, and has reviewed more than 400 clinical phase I, Phase II, Phase III, Phase IV clinical trial plan and pediatric trial plan; Professor Longyao formulated the product development and application strategy of Sino-US double reporting for Shanghai Longyao Bio, which accelerated the pace of Shanghai Longyao Bio’s participation in international competition.
Shanghai Longyao Biotechnology increases the survival rate of cancer patients through innovative immune cell therapy technology, and is committed to becoming a world-class independent innovation company in the field of immune cell therapy, writing a Chinese story of innovative breakthroughs in tumor immune cell therapy.